Inhibrx Biosciences, Inc. INBX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s operating lease liabilities (current)?
- Inhibrx Biosciences, Inc. (INBX) reported operating lease liabilities (current) of $2.41M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s operating lease liabilities (current) changed year-over-year?
- Inhibrx Biosciences, Inc.'s operating lease liabilities (current) increased by 22.0% year-over-year, from $1.97M to $2.41M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s operating lease liabilities (current)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s operating lease liabilities (current) has grown at a 6.2% compound annual growth rate (CAGR), from $2.06M to $2.33M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.